Geoffrey Spolyar focuses his practice on the representation of life sciences companies in a broad range of commercial and financial matters. Much of his practice is devoted to negotiating and drafting corporate partnership agreements, licensing arrangements, strategic alliances, joint venture agreements and other complex technology transactions. 

Download full bio 


  • ERYTECH – $144 Million IPO 

  • ZELTIQ Aesthetics to Sell to Allergan for $2.5 Billion 

  • Cooley Advises on Nightstar + NuCana IPOs 

  • Jazz Pharmaceuticals Acquisition of Redx Pharma's pan-RAF Inhibitor Program Valued up to $206 Million 

  • X4 Pharmaceuticals in its Exclusive License Agreement with Abbisko Therapeutics 

  • View all


  • University of Southern California, Gould School of Law
    JD, 1996

  • University of Michigan, Ann Arbor
    BA, Japanese History

Admissions & Credentials